Monday April 3, 2023
Notice of Results and Investor Presentation
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Full Year Results and Investor Presentation Brighton, United Kingdom – 3 April 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage […]
Friday March 24, 2023
Landmark XF-73 Phase 2 data published in US journal
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology Demonstrates significant reduction of […]
Thursday March 16, 2023
Agreement with Sebela Pharmaceuticals for NTCD-M3
Destiny Pharma PLC Exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals® worth up to $570m plus royalties Partnership with Sebela will finance the future clinical development and commercialization […]
Thursday March 16, 2023
Issue of Equity
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) (THIS “ANNOUNCEMENT”) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, […]
Wednesday January 25, 2023
US Center for Disease Control review paper
Destiny Pharma plc (“Destiny Pharma” or the “Company”) US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections Brighton, […]
Thursday December 22, 2022
Year End Trading Update
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma announces year end Trading Update Good progress across all key projects in 2022 Brighton, United Kingdom – 22 December 2022 […]
Tuesday November 15, 2022
XF-73 Dermal infection project advances into clinically enabling safety study with US Go...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID Brighton, United Kingdom, […]
Thursday September 8, 2022
Interim results for six months ended 30 June 2022
Destiny Pharma today announced its interim results for the 6 months ended 30 June 2022, which can be found here.
Wednesday September 7, 2022
Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Inves...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference Brighton, United Kingdom – 7 September 2022 – […]
Wednesday September 7, 2022